Medically reviewed by Drugs.com. Last updated on March 31, 2020.
Applies to the following strengths: 75 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Migraine
75 mg orally
Maximum dose: 75 mg in a 24-hour period
-This drug is not for the preventive treatment of migraine.
-The safety of treating more than 15 migraines in a 30-day period is unknown.
Use: For the acute treatment of migraine with or without aura.
Renal Dose Adjustments
Mild to Severe Renal Impairment (CrCl 15 mL/min or greater): No adjustment recommended
ESRD (CrCl less than 15 mL/min): Avoid use
Liver Dose Adjustments
Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No adjustment recommended
Severe Hepatic Impairment (Child-Pugh C): Avoid use
Concomitant Use with CYP450 3A4 Inhibitors:
-Strong CYP450 3A4 inhibitors: Avoid concomitant administration
-Moderate CYP450 3A4 inhibitors: Avoid a second dose of rimegepant within 48 hours
Concomitant Use with CYP450 3A4 Inducers:
-Strong or moderate CYP450 3A4 inducers: Avoid concomitant administration as this may lead to loss of efficacy of rimegepant
Concomitant Use with P-gp or BCRP:
-Avoid concomitant administration with P-gp or BCRP inhibitors
-Hypersensitivity to active substance or any product excipients; delayed serious hypersensitivity has occurred
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Place on tongue (or under tongue) and allow to disintegrate in saliva and swallow; additional liquid is not necessary
-Do not take more than 1 dose in 24-hours
-Use dry hands when opening the blister pack
-Peel back the foil and gently remove the tablet; do not push tablet through foil
-Place tablet on tongue or under tongue as soon as the blister is opened
-Do not store table outside the blister pack
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
-Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.